These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 23465281)

  • 41. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
    Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma.
    Hara H; Suda K
    Am J Clin Pathol; 2008 Jan; 129(1):115-29. PubMed ID: 18089497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MUC1 and HER2 might be associated with invasive phenotype of intraductal papillary mucinous neoplasm.
    Ohira G; Kimura K; Yamada N; Amano R; Nakata B; Doi Y; Murata A; Yashiro M; Tanaka S; Ohsawa M; Wakasa K; Hirakawa K
    Hepatogastroenterology; 2013; 60(125):1067-72. PubMed ID: 23635475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Precursors of Pancreatic cancer: Intraepithelial Neoplasia (PanIN) and Intraductal Papillary Mucinous Neoplasms (IPMN)].
    Ledniczky G; Bognár G; Bereczky B; Barabás L; Ondrejka P
    Magy Seb; 2009 Feb; 62(1):22-6. PubMed ID: 19218165
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features.
    Nishikawa N; Kimura Y; Okita K; Zembutsu H; Furuhata T; Katsuramaki T; Kimura S; Asanuma H; Hirata K
    J Hepatobiliary Pancreat Surg; 2006; 13(4):327-35. PubMed ID: 16858545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms.
    Nara S; Shimada K; Kosuge T; Kanai Y; Hiraoka N
    Am J Surg Pathol; 2008 Feb; 32(2):243-55. PubMed ID: 18223327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of clinical meaning of histological subtypes of intraductal papillary mucinous neoplasm of the pancreas.
    Kang MJ; Lee KB; Jang JY; Han IW; Kim SW
    Pancreas; 2013 Aug; 42(6):959-66. PubMed ID: 23462330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas.
    Iacobuzio-Donahue CA; Klimstra DS; Adsay NV; Wilentz RE; Argani P; Sohn TA; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Am J Pathol; 2000 Sep; 157(3):755-61. PubMed ID: 10980115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas.
    Miyasaka Y; Nagai E; Yamaguchi H; Fujii K; Inoue T; Ohuchida K; Yamada T; Mizumoto K; Tanaka M; Tsuneyoshi M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4371-7. PubMed ID: 17671118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): new insights on clinical outcomes and malignant progression.
    Khouri J; Saif MW
    JOP; 2014 Jul; 15(4):310-2. PubMed ID: 25076329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparative study of intraductal papillary neoplasia of the biliary tract and pancreas.
    Kloek JJ; van der Gaag NA; Erdogan D; Rauws EA; Busch OR; Gouma DJ; ten Kate FJ; van Gulik TM
    Hum Pathol; 2011 Jun; 42(6):824-32. PubMed ID: 21292296
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
    Hirono S; Tani M; Kawai M; Ina S; Nishioka R; Miyazawa M; Fujita Y; Uchiyama K; Yamaue H
    Arch Surg; 2009 Apr; 144(4):345-9; discussion 349-50. PubMed ID: 19380648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas.
    Basturk O; Chung SM; Hruban RH; Adsay NV; Askan G; Iacobuzio-Donahue C; Balci S; Zee SY; Memis B; Shia J; Klimstra DS
    Virchows Arch; 2016 Nov; 469(5):523-532. PubMed ID: 27591765
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas.
    Jang JY; Park YC; Song YS; Lee SE; Hwang DW; Lim CS; Lee HE; Kim WH; Kim SW
    J Hepatobiliary Pancreat Surg; 2009; 16(5):668-74. PubMed ID: 19412570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pancreatic intraepithelial neoplasia revisited and updated.
    Sipos B; Frank S; Gress T; Hahn S; Klöppel G
    Pancreatology; 2009; 9(1-2):45-54. PubMed ID: 19077454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency of subtypes of biliary intraductal papillary mucinous neoplasm and their MUC1, MUC2, and DPC4 expression patterns differ from pancreatic intraductal papillary mucinous neoplasm.
    Sclabas GM; Barton JG; Smyrk TC; Barrett DA; Khan S; Kendrick ML; Reid-Lombardo KM; Donohue JH; Nagorney DM; Que FG
    J Am Coll Surg; 2012 Jan; 214(1):27-32. PubMed ID: 22112419
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
    Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
    Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. aPKCλ/ι is a beneficial prognostic marker for pancreatic neoplasms.
    Kato S; Akimoto K; Nagashima Y; Ishiguro H; Kubota K; Kobayashi N; Hosono K; Watanabe S; Sekino Y; Sato T; Sasaki K; Nakaigawa N; Kubota Y; Inayama Y; Endo I; Ohno S; Maeda S; Nakajima A
    Pancreatology; 2013; 13(4):360-8. PubMed ID: 23890134
    [TBL] [Abstract][Full Text] [Related]  

  • 59. P53 expression in invasive pancreatic adenocarcinoma and precursor lesions.
    Norfadzilah MY; Pailoor J; Retneswari M; Chinna K; Noor LM
    Malays J Pathol; 2011 Dec; 33(2):89-94. PubMed ID: 22299208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas.
    Sasaki S; Yamamoto H; Kaneto H; Ozeki I; Adachi Y; Takagi H; Matsumoto T; Itoh H; Nagakawa T; Miyakawa H; Muraoka S; Fujinaga A; Suga T; Satoh M; Itoh F; Endo T; Imai K
    Oncol Rep; 2003; 10(1):21-5. PubMed ID: 12469138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.